Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 16/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25827570 | 0.89 | LOXL2 (0.42) | CACNA2D1MCHR1 | |
| SCHEMBL2586363 | 0.83 | CACNA2D1 (0.49) | CACNA2D1 | |
| SCHEMBL9601934 | 0.78 | SYK (0.54) | CACNA2D1NR3C1 | |
| SCHEMBL2608852 | 0.78 | NR3C1 (0.54) | CACNA2D1NR3C1 | |
| SCHEMBL25823363 | 0.77 | MCHR1 (0.42) | CACNA2D1MCHR1 | |
| SCHEMBL28062487 | 0.77 | CACNA2D1 (0.47) | CACNA2D1 | |
| SCHEMBL25823870 | 0.77 | MCHR1 (0.41) | CACNA2D1MCHR1 | |
| SCHEMBL8029698 | 0.76 | MCHR1 (0.64) | MCHR1 | |
| SCHEMBL6274946 | 0.76 | KMT2A (0.50) | CACNA2D1 | |
| SCHEMBL3133596 | 0.76 | KMT2A (0.50) | CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CACNA2D1 3400/4885MCHR1 4479/4885NR3C1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.